UNSPSC 51361916: Methitural

This classification denotes a barbiturate with the molecular formula C12H20N2O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DZQ457UJ3Y, chemically known as 4,6-(1h,5h)-pyrimidinedione, dihydro-5-(1-methylbutyl)-5-(2-(methylthio)ethyl)-2-thioxo- but generally known as methitural, which bears US NIH Compound Identifier 3032307. European Medicines Agency schedules Methitural in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08851MIG.

UNSPSC 51361916 Methitural is a Commodity code that captures state and local procurement of pharmaceutical products, including generic multi-source medications, over-the-counter items, and emergency health-response pharmaceuticals such as naloxone. State and local issuing bodies soliciting under this code include county health departments, state health and human services commissions, and cooperative purchasing alliances serving multiple jurisdictions. Recent activity shows procurement of naloxone and drug deactivation systems for community health initiatives, generic pharmaceuticals through multi-state cooperative agreements, and exploratory procurements for direct-to-manufacturer prescription programs. These solicitations reflect both routine pharmaceutical supply contracts and strategic initiatives to optimize pharmacy benefit management and emergency-response medication availability.

Recent opportunities span Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023; the contract includes a two-year initial term with optional one-year renewal and is potentially funded through FEMA. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, signaling the state's intent to explore alternative pharmacy benefit contracting models before issuing a formal RFP. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by Minnesota's Department of Administration Office of State Procurement, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products serving participating state and local government facilities in Minnesota and Oregon, with proposals due March 26, 2026, and contract effectiveness on July 1, 2026; evaluation weighting emphasized price competitiveness at 75 percent, with vendors required to maintain relationships with authorized wholesalers and comply with cGMP and Drug Supply Chain Security Act standards.